SPSudhakar Pipavath

Sudhakar Pipavath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sudhakar Pipavath has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

    Supplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer

  • Open Access

    Figure S5 from T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

    Validation of TCR disease status prediction on a CMV cohort

  • Open Access

    Data from T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

    The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.

  • Open Access

    Figure S3 from T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

    TCRβ sequences belonging to both TILS-A and TILS-B classifiers

  • Open Access

    Figure S1 from T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

  • T-cell Receptor Profiling of Blood to Detect Lung Cancer

    by Maria T. Søgaard, Diane Tseng, Sarah Gibbs, Wei Wu, Lorna G. Nolan, Pamela Y. Yang, Mason Lai, Jianhong Cao, Sudhakar Pipavath, Koshlan Mayer-Blackwell, et al.

    The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.


  • Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness

    by Eric D. Morrell, Pavan K. Bhatraju, Neha A. Sathe, Jonathan Lawson, Linzee Mabrey, Sarah E. Holton, Scott R. Presnell, Alice Wiedeman, Carolina Acosta-Vega, Mallorie A. Mitchem, et al.

    Critically ill patients manifest many of the same immune features seen in coronavirus disease 2019 (COVID-19), including both “cytokine storm” and “immune suppression.” However, direct comparisons of molecular and cellular profiles between contemporaneously enrolled critically ill patients with and without severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited. We sought to identify immune signatures specifically enriched in critically ill patients with COVID-19 compared with patients without COVID-19. We enrolled a multisite prospective cohort of patients admitted under suspicion for COVID-19, who were then determined to be SARS-CoV-2-positive (n = 204) or -negative (n = 122). SARS-CoV-2-positive patients had higher plasma levels of CXCL10, sPD-L1, IFN-γ, CCL26, C-reactive protein (CRP), and TNF-α relative to SARS-CoV-2-negative patients adjusting for demographics and severity of illness (Bonferroni P value < 0.05). In contrast, the levels of IL-6, IL-8, IL-10, and IL-17A were not significantly different between the two groups. In SARS-CoV-2-positive patients, higher plasma levels of sPD-L1 and TNF-α were associated with fewer ventilator-free days (VFDs) and higher mortality rates (Bonferroni P value < 0.05). Lymphocyte chemoattractants such as CCL17 were associated with more severe respiratory failure in SARS-CoV-2-positive patients, but less severe respiratory failure in SARS-CoV-2-negative patients (P value for interaction < 0.01). Circulating T cells and monocytes from SARS-CoV-2-positive subjects were hyporesponsive to in vitro stimulation compared with SARS-CoV-2-negative subjects. Critically ill SARS-CoV-2-positive patients exhibit an immune signature of high interferon-induced lymphocyte chemoattractants (e.g., CXCL10 and CCL17) and immune cell hyporesponsiveness when directly compared with SARS-CoV-2-negative patients. This suggests a specific role for T-cell migration coupled with an immune-checkpoint regulatory response in COVID-19-related critical illness.


  • Radiographic Findings and Association With Clinical Severity and Outcomes in Critically Ill Patients With COVID-19

    by Wei Wu, Pavan K. Bhatraju, Natalie Cobb, Neha A. Sathe, Kevin I. Duan, Kevin P. Seitz, Matthew R. Thau, Clifford C. Sung, Daniel S. Hippe, Gautham Reddy, et al.

  • Top Cited Papers

    Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

    by Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, et al.

    Background: This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Methods: The evidence syntheses were discussed and recommendations formulated by a multidisciplinary committee of IPF experts. The evidence was appraised and recommendations were formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: The guideline panel updated the diagnostic criteria for IPF. Previously defined patterns of usual interstitial pneumonia (UIP) were refined to patterns of UIP, probable UIP, indeterminate for UIP, and alternate diagnosis. For patients with newly detected interstitial lung disease (ILD) who have a high-resolution computed tomography scan pattern of probable UIP, indeterminate for UIP, or an alternative diagnosis, conditional recommendations were made for performing BAL and surgical lung biopsy; because of lack of evidence, no recommendation was made for or against performing transbronchial lung biopsy or lung cryobiopsy. In contrast, for patients with newly detected ILD who have a high-resolution computed tomography scan pattern of UIP, strong recommendations were made against performing surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy, and a conditional recommendation was made against performing BAL. Additional recommendations included a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs. Conclusions: The guideline panel provided recommendations related to the diagnosis of IPF.